108 completed, 44 terminated, 28 recruiting, 27 unknown. 245 Phase 2, 67 Phase 1, 4 Phase 3.
Follow Metastatic Cancer: new trials by email Literature Review of Metastatic Cancer trials Research Report on Metastatic Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | CHU de Quebec-Universite Laval | 500 | 2028-03-01 | 2025-03-30 |
| Real-world Trial of Individualized Precision Oncology Molecularly matched therapy, Standard of care - Metastatic Cancer, Unresectable Carcinoma | Phase 2 | Not yet recruiting | University of California, San Diego | 280 | 2026-12-01 | 2026-09-03 |
| Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases. LATTICE Radiotherapy, Standard radiotherapy - Metastases, Metastatic Cancer | Phase 2 | Recruiting | Stanford University | 80 | 2026-08-28 | 2026-09-09 |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) Givastomig, Nivolumab, 5Fluorouracil - Solid Tumor, Advanced Cancer | Phase 2 | Recruiting | I-Mab Biopharma US Limited | 180 | 2026-02-11 | 2026-05-14 |
| Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases Bevacizumab - Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Active not recruiting | Pardis Noor Medical Imaging and Cancer Center | 40 | 2025-06-01 | 2026-09-16 |
| Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer Ivosidenib (AK112) - CRC, MSS | Phase 2 | Not yet recruiting | Fudan University | 36 | 2024-11-01 | 2024-09-19 |
| Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors Lattice therapy (LRT) - Cancer, Metastatic Cancer | Phase 2 | Recruiting | University of Cincinnati | 37 | 2024-08-02 | 2026-05-04 |
| Biomarkers to Detect Endocrine Therapy Resistance 18F-fluorofuranylnorprogesterone, Liquid Biopsy, Positron Emission Tomography/Computed Tomography - Metastatic Cancer, Breast Cancer | Phase 2 | Recruiting | University of Wisconsin, Madison | 8 | 2024-04-30 | 2026-08-25 |
| Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) Adagrasib - Advanced Cancer, Metastatic Cancer | Phase 2 | Active not recruiting | Mirati Therapeutics Inc. | 200 | 2024-02-01 | 2026-08-14 |
| Definitive Radiation for High-Risk Spine Metastases SBRT to the spine - Metastatic Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | Stony Brook University | 26 | 2023-12-14 | 2025-05-14 |
| A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer [177Lu]Lu-SN201 - Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Spago Nanomedical AB | 90 | 2023-12-06 | 2025-11-20 |
| Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases Azeliragon, Stereotactic radiosurgery, Corticosteroid - Cancer, Metastasis | Phase 1 / Phase 2 | Suspended | Baptist Health South Florida | 46 | 2023-11-17 | 2026-06-16 |
| FIH XON7 in Advanced/Metastatic Solid Tumors XON7 - Advanced Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Xenothera SAS | 255 | 2023-11-14 | 2026-08-20 |
| A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents OR502, Cemiplimab - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Recruiting | OncoResponse, Inc. | 168 | 2023-10-24 | 2025-01-07 |
| Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Trastuzumab deruxtecan - Brain Cancer, Glioblastoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2023-09-22 | 2026-02-23 |
| Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer CJRB-101, Pembrolizumab injection - NSCLC, HNSCC | Phase 1 / Phase 2 | Recruiting | CJ Bioscience, Inc. | 160 | 2023-09-11 | 2024-12-20 |
| Study of ART0380 in Patients With Biologically Selected Solid Tumors ART0380 - Advanced Solid Tumor, Recurrent Endometrial Cancer | Phase 2 | Terminated | Artios Pharma Ltd | 36 | 2023-09-06 | 2025-11-06 |
| A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma Pemetrexed, Zimberelimab, Etrumadenant - Urothelial Carcinoma, Metastatic Cancer | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 10 | 2023-06-13 | 2026-08-14 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
Showing 20 of 245. Sign in to see all of them.
Neoplasm Metastasis (245) · Colorectal Neoplasms (48) · Brain Neoplasms (37) · Colonic Neoplasms (37) · Carcinoma, Non-Small-Cell Lung (34) · Melanoma (32) · Rectal Neoplasms (30) · Neoplasms (27) · Breast Neoplasms (22) · Carcinoma, Renal Cell (22) · Lung Neoplasms (22) · Prostatic Neoplasms (19) · Kidney Neoplasms (17) · Ovarian Neoplasms (17) · Carcinoma, Hepatocellular (14)
Neoplastic Processes (245) · Pathologic Processes (245) · Pathological Conditions, Signs and Symptoms (245) · Neoplasms (218) · Neoplasms by Site (186) · Neoplasms by Histologic Type (90) · Digestive System Diseases (78) · Digestive System Neoplasms (78) · Neoplasms, Glandular and Epithelial (73) · Gastrointestinal Diseases (67) · Gastrointestinal Neoplasms (64) · Carcinoma (59) · Urogenital Diseases (59) · Urogenital Neoplasms (59) · Intestinal Diseases (53)
Fluorouracil (21) · Leucovorin (20) · pembrolizumab (19) · Oxaliplatin (17) · Bevacizumab (16) · Irinotecan (14) · Cetuximab (12) · Nivolumab (12) · Cyclophosphamide (11) · Radiosurgery (11) · Capecitabine (10) · Radiofrequency Ablation (10) · aldesleukin (10) · Radiotherapy (9) · Ipilimumab (8)
M.D. Anderson Cancer Center (11) · Memorial Sloan Kettering Cancer Center (10) · National Cancer Institute (NCI) (9) · Alliance for Clinical Trials in Oncology (7) · Amgen (7) · Duke University (5) · UNICANCER (5) · Eastern Cooperative Oncology Group (4) · Fudan University (4) · Incyte Biosciences International Sàrl (4) · National Institutes of Health Clinical Center (CC) (4) · SWOG Cancer Research Network (4) · Case Comprehensive Cancer Center (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Radiation Therapy Oncology Group (3)
United States (155) · France (29) · Canada (15) · Spain (15) · United Kingdom (15) · China (13) · Australia (12) · Belgium (10) · South Korea (10) · Germany (6) · Italy (6) · Japan (5) · Switzerland (5) · Taiwan (5) · Israel (4)
Steven A Rosenberg, M.D. (5) · Darell D. Bigner, MD, PhD (3) · Svetomir Markovic, MD, PhD (3) · Christopher Logothetis, MD (2) · David M. Peereboom, MD (2) · H. Richard Alexander, MD, FACS (2) · Hamidreza Aliabadi, MD (2) · James E. Herndon, PhD (2) · John E. Janik, MD (2) · John H. Sampson, MD, PhD (2) · John P. Kirkpatrick, MD (2) · Kenneth L. Pennington, MD (2)
PMID 38421252, PMID 14673042, PMID 16009952, PMID 16230673, PMID 16314647, PMID 17418968, PMID 17987262, PMID 18008108, PMID 20042969, PMID 20576718, PMID 20595147, PMID 21290244, PMID 21784628, PMID 22070868, PMID 22093943, PMID 22431703, PMID 23122784, PMID 23361051, PMID 23377668, PMID 23657083, PMID 23861247, PMID 23990665, PMID 24013510, PMID 24268852, PMID 24646562, PMID 24890347, PMID 25175099, PMID 25349290, PMID 25355723, PMID 25432172, PMID 25614945, PMID 25695221, PMID 26010778, PMID 26148750, PMID 28408243, PMID 29151359, PMID 29186319, PMID 29290249, PMID 29438373, PMID 31584608, PMID 31595044, PMID 32208873, PMID 32398040, PMID 33270906, PMID 33386290, PMID 33570247, PMID 33581798, PMID 33847874, PMID 34161704, PMID 34213592
2016 (5), P30CA016672 (5), U10CA032102 (4), 2023 (3), P30CA043703 (3), P30CA022453 (2), P30CA033572 (2), U10CA021115 (2), 2008 (1), 2015 (1), 2018 (1), 2019 (1), P30CA008748 (1), P30CA012197 (1), P30CA014236 (1)